AMnESTI reverses age-associated lung immune decline to drive heterosubtypic protection by inactivated influenza vaccines.

AMnESTI reverses age-related decline in lung immunity, enabling complete heterosubtypic protection by influenza vaccines in aged mice.

• Why it matters: Limited vaccine efficacy in the elderly and failure to elicit broad immunity highlight the need for improved adjuvants that restore immune function in aging lungs.
• What they did: Researchers developed AMnESTI, an intranasal liposomal STING agonist targeting alveolar epithelial cells, and tested its effects on lung immune responses and vaccine protection in aged mice.
• The result: A single dose of AMnESTI-adjuvanted vaccine revived aged lung immunity to a youthful, proimmune state and provided full heterosubtypic protection against influenza strains, suggesting a promising strategy for elderly vaccination.